These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30529793)

  • 1. Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa.
    Griesinger G; Teal V; McCrary Sisk C; Ruman J
    Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():101-105. PubMed ID: 30529793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
    Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
    Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
    Souza PMG; Carvalho BR; Nakagawa HM; Rassi TRE; Barbosa ACP; Silva AA
    JBRA Assist Reprod; 2017 Jun; 21(2):67-69. PubMed ID: 28609269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of gonadotropin type on progesterone elevation during ovarian stimulation in GnRH antagonist cycles.
    Lawrenz B; Beligotti F; Engelmann N; Gates D; Fatemi HM
    Hum Reprod; 2016 Nov; 31(11):2554-2560. PubMed ID: 27619773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.
    Blockeel C; Polyzos NP; Derksen L; De Brucker M; Vloeberghs V; van de Vijver A; De Vos M; Tournaye H
    Hum Reprod; 2014 Jul; 29(7):1500-7. PubMed ID: 24813196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
    Devroey P; Boostanfar R; Koper NP; Mannaerts BM; Ijzerman-Boon PC; Fauser BC;
    Hum Reprod; 2009 Dec; 24(12):3063-72. PubMed ID: 19684043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis.
    Griesinger G; Boostanfar R; Gordon K; Gates D; McCrary Sisk C; Stegmann BJ
    Reprod Biomed Online; 2016 Jul; 33(1):56-60. PubMed ID: 27178762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
    Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
    Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis.
    Fensore S; Di Marzio M; Tiboni GM
    J Ovarian Res; 2015 Jun; 8():33. PubMed ID: 26036214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone.
    Boostanfar R; Mannaerts B; Pang S; Fernandez-Sanchez M; Witjes H; Devroey P;
    Fertil Steril; 2012 Jun; 97(6):1351-8. PubMed ID: 22459628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction.
    Croxtall JD; McKeage K
    BioDrugs; 2011 Aug; 25(4):243-54. PubMed ID: 21815699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is corifollitropin alfa effective in controlled ovarian stimulation among all poor ovarian responders? A retrospective comparative study.
    Andrisani A; Marin L; Ragazzi E; Donà G; Bordin L; Dessole F; Armanini D; Esposito F; Vitagliano A; Sabbadin C; Ambrosini G
    Gynecol Endocrinol; 2019 Oct; 35(10):894-898. PubMed ID: 31081709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.
    Wang HL; Lai HH; Chuang TH; Shih YW; Huang SC; Lee MJ; Chen SU
    PLoS One; 2016; 11(4):e0154123. PubMed ID: 27100388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.